Suppr超能文献

[监狱中丙型肝炎病毒的筛查与治疗:十年经验]

[Screening and treatment of hepatitis C virus in prisons: 10 years of experience].

作者信息

Werling Klára, Makara Mihály, Nemesi Krisztina, Horváth Gábor, Schneider Ferenc, Bali Ildikó, Enyedi Judit, Jancsik Viktor, Káfony András, Lesch Miklós, Lombay Béla, Müller Zsófia, Ozsvár Zsófia, Patai Árpád, Péterfi Zoltán, Pusztay Margit, Szabó Olga, Szlávik János, Tóth Tamás, Varga Márta, Gács Judit, Újhelyi Eszter, Nemes Nagy Anna

机构信息

1 Semmelweis Egyetem, Általános Orvostudományi Kar, Sebészeti, Transzplantációs és Gasztroenterológiai Klinika Budapest, Üllői út 78., 1082 Magyarország.

2 Dél-pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, Szent László Telephely Budapest Magyarország.

出版信息

Orv Hetil. 2022 May 29;163(22):871-878. doi: 10.1556/650.2022.32492.

Abstract

Introduction and objective: Two-thirds of patients with hepatitis C virus (HCV) infection are unaware of their infection in the European Union. The WHO aims to reduce the number of new cases of chronic hepatitis by 90% by 2030. The proportion of people infected with HCV in prisons can be up to ten times higher compared to the general population. This article is a summary of the results of the HCV screening carried out in the Hungarian prisons between 2007 and 2017. Method: Screening of anti-HCV antibodies has been performed on a voluntary basis followed by HCV PCR and genotyping in positive cases. After obtaining written informed consent from the patients, treatment was started. Treatments were performed under the guidance of hepatologists in collaboration with prison medical staff. Results: HCV screening programs and treatments are in place in 84% of Hungarian prisons. A total of 25 384 patients underwent anti-HCV screening. Anti-HCV positive result was detected in 6.6% and HCV PCR positivity was confirmed in 3.8% of the screened inmates. 55.2% patients from the HCV PCR positive population were put on treatment. Only 143 patients received full treatment, while 162 (42.6%) treatments were terminated prematurely, and the duration of treatment was unknown in 75 patients. Based on the results available on the 24th week after the end of treatment, sustained virologic response rate was 88%. Discussion: Education of patients and collaboration between hepatologists and prison medical staff play an important role in the successful result of treatment. Conclusion: Our experience demonstrates that the test and treat principle is feasible and effective at microeliminating HCV in prisons.

摘要

引言与目的

在欧盟,三分之二的丙型肝炎病毒(HCV)感染者并不知道自己已被感染。世界卫生组织的目标是到2030年将慢性肝炎新发病例数减少90%。监狱中感染HCV的人群比例相比普通人群可能高达10倍。本文是2007年至2017年期间在匈牙利监狱开展的HCV筛查结果总结。方法:自愿进行抗-HCV抗体筛查,阳性病例随后进行HCV PCR检测和基因分型。在获得患者书面知情同意后开始治疗。治疗在肝病专家指导下,由监狱医务人员协作进行。结果:84%的匈牙利监狱设有HCV筛查项目和治疗措施。共有25384名患者接受了抗-HCV筛查。筛查出的囚犯中,抗-HCV阳性结果占6.6%,HCV PCR阳性占3.8%。HCV PCR阳性人群中有55.2%的患者接受了治疗。只有143名患者接受了全程治疗,162例(42.6%)治疗提前终止,75例患者治疗时长未知。根据治疗结束后第24周的现有结果,持续病毒学应答率为88%。讨论:患者教育以及肝病专家与监狱医务人员之间的协作对治疗的成功结果起着重要作用。结论:我们的经验表明,检测和治疗原则在监狱中微消除HCV方面是可行且有效的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验